City of Hope | Strategic Alliance Partners

Richard T. Lee, MD, and Edward S. Kim, MD, MBA, discuss the benefits of integrative oncology and exploring integrative approaches at the Cherng Family Center for Integrative Oncology at City of Hope.

Jasmine Zain, MD, director of the T-cell Lymphoma Program, professor of hematology and hematopoietic stem cell transplantation, of City of Hope National Medical Center, discusses the challenges of treatment for patients with T-cell lymphoma.

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

Richard T. Lee, MD, discusses integrative oncology approaches and the development of the Cherng Family Center for Integrative Oncology at City of Hope.

Daneng Li, MD, discusses the implications of a study evaluating ADG126 in combination with pembrolizumab in patients with MSS colorectal cancer.

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts explain the challenges faced with preventing or detecting these cancers early and the understanding needed to develop effective early detection methods and move the needle forward.

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.

Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

Joseph Mikhael, MD, discusses unmet needs that remain to be addressed in the treatment of patients with multiple myeloma.

Two items in the medical world should send chills down the spines of those considering the possible financial future of oncology care in the United States.

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

Side effect profiles driven by fruquintinib use are discussed.

Dr Lunning sits down with Alex Herrera, MD, to discuss the frontline management of Hodgkin lymphoma, including the SWOG 1826 trial.

Initial antitumor activity and safety data have been observed in the phase 1 portion of a phase 1/2a trial of IMM-1-104 in RAS-mutant solid tumors.

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

Key safety considerations for the use of fruquintinib are explored.

Speculation on anticipated innovations in allo-HSCT and cellular therapy technologies in the future.

The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.